Managing Itch Among Patients with Atopic Dermatitis, with Gil Yosipovitch, MD
In this interview, Yosipovitch touches on the topics featured in his RAD 2025 presentation ‘Managing Itch,’ specifically regarding patients with atopic dermatitis.
Related Articles
Adding Upadacitinib to the Treatment Landscape of GCA, with Daniel Blockmans, MD, PhD
Blockmans discussed data supporting upadacitinib’s new indication and why the approval is important for patients with giant cell arteritis.
Discussing Dose Flexibility in Adult Atopic Dermatitis, with Tejesh Patel, MD
This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.
Study Describes Racial, Ethnic Disparities in Pediatric Alopecia Areata Prevalence
A high alopecia areata burden was seen among US Asian and Pacific Islander children, particularly South Asian, Filipino, Vietnamese, and Native Hawaiian/Pacific Islander subgroups.
Sexual Dysfunction in Those with Androgenetic Alopecia on Dutasteride Versus Finasteride
These data highlight the adverse events resulting from the use of dutasteride and finasteride in treating androgenetic alopecia.
Breaking Down Biologics in Atopic Dermatitis: Choosing the Right Path for Patients
Melodie Young, MSN, AGNP-C, FSDNP, DCNP; TJ Chao, MPAS, PA-C; Leigh Ann Pansch, MSN, FNP-BC, DCNP; and Douglas DiRuggiero, DMSc, MHS, PA-C, discuss how the…
Allergy | Medical News & Expert Perspectives | HCPLive
The allergy condition center is a comprehensive resource for clinical news and expert insights on allergy. Read more at HCPLive.
Predicting Cardiovascular Disease in Patients Without Risk Factors with Matthew Budoff, MD
Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.
Efficacy, Safety of Deucravacitinib for Psoriasis, with Milaan Shah, MD
In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.
FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation
Parent company Amneal Pharmaceuticals, Inc. has announced intentions to launch the topical anti-inflammatory agent in the third quarter of 2025.
Leveraging SGLT2 Inhibitors, GLP-1 RAs in Heart Failure, with Jose Lopez, MD
Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.